Constellation Pharmaceuticals to Host Conference Call to Discuss Fourth Quarter 2020 Results
18 févr. 2021 10h00 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...
Global High Resolution Melting Analysis Market (2020 to 2026) - Featuring Agilent Technologies, Azura Genomics & Biomerieux Among Others
17 févr. 2021 07h13 HE
|
Research and Markets
Dublin, Feb. 17, 2021 (GLOBE NEWSWIRE) -- The "High Resolution Melting Analysis Market Value forecast, New Business Opportunities and Companies: Outlook by Type, Application, by End User and by...
Constellation Pharmaceuticals Appoints Brendan Delaney as Chief Commercial Officer
07 janv. 2021 09h30 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced the appointment of Brendan Delaney to the newly created position of Chief...
Constellation Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
06 janv. 2021 10h00 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that Jigar Raythatha, CEO, will present a company overview at the J.P....
Constellation Pharmaceuticals Provides Update of MANIFEST Study for CPI-0610 at ASH Meeting
06 déc. 2020 08h00 HE
|
Constellation Pharmaceuticals , Inc.
67% spleen volume response rate observed in 63 first-line myelofibrosis patients treated with CPI-0610 + ruxolitinib at 24 weeksCPI-0610 demonstrated activity, both as a monotherapy and as add on to...
Constellation Pharmaceuticals to Host Analyst / Investor Event to Discuss Update of MANIFEST Clinical Trial for CPI-0610 Presented at ASH Meeting
23 nov. 2020 13h00 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
Constellation Pharmaceuticals Announces Third-Quarter 2020 Financial Results
29 oct. 2020 07h00 HE
|
Constellation Pharmaceuticals , Inc.
MANIFEST data update planned for the American Society of Hematology (ASH) meeting in December CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a...
Constellation Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2020 Results
19 oct. 2020 14h00 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...
Forecast [2019-2026] Epigenetics Market Size, Share, Growth, Trends, Analysis, Revenue, Competitive Landscape, Report
14 oct. 2020 07h38 HE
|
Fortune Business Insights
Pune, Oct. 14, 2020 (GLOBE NEWSWIRE) -- The global epigenetics market is set to gain impetus from the increasing governmental and institutional collaborations worldwide for the study of cancer....
Global $4.88 Bn CRISPR & Cas Genes Market to 2027: Opportunities in the Expanding Gene & Cell Therapy Area & Government Fund In Genomic R&D
21 sept. 2020 05h18 HE
|
Research and Markets
Dublin, Sept. 21, 2020 (GLOBE NEWSWIRE) -- The "Global CRISPR & Cas Genes Market Size, Share & Trends Analysis by Product & Service (Vector-based Cas, DNA-free Cas, Cell Line...